3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
183
Other solid neoplasm
183
Gastrointestinal
18
Genitourinary
16
Gynecologic
13
Breast
10
Dermatologic
8
Sarcoma
7
Head & Neck
7
Endocrine
4
Other hematologic neoplasm
2
Myeloid
2
Lymphoid
2
CNS
2
Plasma cell
1
Other neoplasm
1
NET
1
Conditions
Neuroendocrine Tumors
378
Carcinoid Tumor
40
Gastro-enteropancreatic neuroendocrine tumor
36
Pancreatic Neoplasms
27
Carcinoma, Neuroendocrine
27
Neoplasms
25
Adenoma, Islet Cell
23
Pheochromocytoma
17
Paraganglioma
17
Neoplasm Metastasis
17
Stomach Neoplasms
15
Neuroblastoma
14
Gastrointestinal Neoplasms
14
Carcinoma, Hepatocellular
12
Thyroid Neoplasms
11
Prostatic Neoplasms
11
Breast Neoplasms
11
Sarcoma
10
Esophageal Neoplasms
10
Colorectal Neoplasms
10
Lung Neoplasms
9
Rectal Neoplasms
8
Gastrointestinal Stromal Tumors
8
Cholangiocarcinoma
8
Carcinoma, Medullary
8
Carcinoma
8
Brain Neoplasms
8
Anus Neoplasms
8
Liver Neoplasms
7
Colonic Neoplasms
7
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mesothelioma, Malignant
×
NET
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled